Janus Henderson Group PLC Cuts Stock Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Janus Henderson Group PLC decreased its holdings in ABIVAX Société Anonyme (NASDAQ:ABVX) by 65.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 410,710 shares of the company’s stock after selling 764,804 shares during the quarter. Janus Henderson Group PLC owned 0.65% of ABIVAX Société Anonyme worth $4,740,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares in the last quarter. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the period. Finally, abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Up 0.9 %

NASDAQ:ABVX opened at $8.58 on Wednesday. ABIVAX Société Anonyme has a 1 year low of $8.06 and a 1 year high of $17.02. The stock has a 50-day simple moving average of $9.62 and a 200-day simple moving average of $11.44.

Analysts Set New Price Targets

Several research analysts recently commented on ABVX shares. JMP Securities assumed coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They set an “outperform” rating and a $33.00 target price for the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $38.67.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.